palmitoyl-l-carnitine Palmitoylcarnitine - an overview Carnitine hexadecanoyl ester Entry of octanoate, palmitoyl-carnitine (PC),

H tr iu tr ng c thy ngn lm gim nng thy ngn trong mu

2Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)] 3Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11-fold increase in exposure) Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs EE = ethinyl estradiol, NG = norgestrel, QD= Once daily 1 Clinically significant pharmacodynamic effects [see Drug Interactions (7.3)] 2Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure) Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins

J Neurosci Res 47:9097 Rogers SA (2003) Lipoic acid as a potential first agent for protection from mycotoxins and treatment of mycotoxicosis

Nephrol Dial Transpl 14:910918